Clinical and biologic characteristics of patients
. | No. . | . | . | |
|---|---|---|---|---|
. | Imatinib group (n = 29) . | Historical group (n = 33) . | P . | |
| Median age, y (range) | 36 (18-55) | 35 (15-48) | .160 | |
| Sex | .622 | |||
| Male (%) | 14 (48.3) | 18 (54.5) | ||
| Female (%) | 15 (51.7) | 15 (45.5) | ||
| Median hemoglobin level, g/dL (range) | 9.9 (4.9-13.5) | 8.5 (3.8-13.7) | .205 | |
| Median WBC count, × 109/L (range) | 32.3 (1.8-239.0) | 50.3 (1.6-481.0) | .658 | |
| Median platelet count, × 109/L (range) | 42.0 (12.0-313.0) | 33.0 (9.0-131.0) | .402 | |
| Median LDH level, IU/L (range) | 1173 (442-6366) | 1767 (250-4188) | .494 | |
| Extramedullary involvement | .987 | |||
| Yes (%) | 14 (48.3) | 16 (48.5) | ||
| No (%) | 15 (51.7) | 17 (51.5) | ||
| CNS leukemia | .926 | |||
| Yes (%) | 1 (3.6) | 1 (3.0) | ||
| No (%) | 28 (96.4) | 32 (97.0) | ||
| Immunophenotype | .814 | |||
| B-lineage (%) | 21 (72.4) | 23 (69.7) | ||
| B + myeloid antigen (%) | 8 (27.6) | 10 (30.3) | ||
| Karyotype | .599 | |||
| Ph alone (%) | 13 (44.8) | 17 (51.5) | ||
| Additional changes (%) | 16 (55.2) | 16 (48.5) | ||
| BCR-ABL subtype | .773 | |||
| p210BCR-ABL (%) | 13 (44.8) | 16 (48.5) | ||
| p190BCR-ABL (%) | 16 (55.2) | 17 (51.5) | ||
| Response to induction therapy | .803 | |||
| CR (%) | 23 (79.3) | 27 (81.8) | ||
| Refractory (%) | 6 (20.7) | 6 (18.2) | ||
| Median time to SCT*, d (range) | 138 (56-217) | 150 (130-234) | .137 | |
. | No. . | . | . | |
|---|---|---|---|---|
. | Imatinib group (n = 29) . | Historical group (n = 33) . | P . | |
| Median age, y (range) | 36 (18-55) | 35 (15-48) | .160 | |
| Sex | .622 | |||
| Male (%) | 14 (48.3) | 18 (54.5) | ||
| Female (%) | 15 (51.7) | 15 (45.5) | ||
| Median hemoglobin level, g/dL (range) | 9.9 (4.9-13.5) | 8.5 (3.8-13.7) | .205 | |
| Median WBC count, × 109/L (range) | 32.3 (1.8-239.0) | 50.3 (1.6-481.0) | .658 | |
| Median platelet count, × 109/L (range) | 42.0 (12.0-313.0) | 33.0 (9.0-131.0) | .402 | |
| Median LDH level, IU/L (range) | 1173 (442-6366) | 1767 (250-4188) | .494 | |
| Extramedullary involvement | .987 | |||
| Yes (%) | 14 (48.3) | 16 (48.5) | ||
| No (%) | 15 (51.7) | 17 (51.5) | ||
| CNS leukemia | .926 | |||
| Yes (%) | 1 (3.6) | 1 (3.0) | ||
| No (%) | 28 (96.4) | 32 (97.0) | ||
| Immunophenotype | .814 | |||
| B-lineage (%) | 21 (72.4) | 23 (69.7) | ||
| B + myeloid antigen (%) | 8 (27.6) | 10 (30.3) | ||
| Karyotype | .599 | |||
| Ph alone (%) | 13 (44.8) | 17 (51.5) | ||
| Additional changes (%) | 16 (55.2) | 16 (48.5) | ||
| BCR-ABL subtype | .773 | |||
| p210BCR-ABL (%) | 13 (44.8) | 16 (48.5) | ||
| p190BCR-ABL (%) | 16 (55.2) | 17 (51.5) | ||
| Response to induction therapy | .803 | |||
| CR (%) | 23 (79.3) | 27 (81.8) | ||
| Refractory (%) | 6 (20.7) | 6 (18.2) | ||
| Median time to SCT*, d (range) | 138 (56-217) | 150 (130-234) | .137 | |
WBC indicates white blood cell; LDH, lactate dehydrogenase; CNS, central nervous system; Ph, Philadelphia chromosome; CR, complete remission; SCT, allogeneic stem cell transplantation.
Interval from the start of induction chemotherapy to the date of transplantation